Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70503 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Rachael A Pellegrino und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: HIV Infections, Uterine Cervical Neoplasms, Early Detection of Cancer, Anus Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Cancer remains a leading cause of morbidity and mortality in people with HIV, and the importance of cancer screening increases as this population ages. In 2017, 2020, and 2023, cross‐sectional surveys were conducted at HIV care sites across 5 continents within the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. We described cancer screening availability in 2023 and over time for cervical and anal cancer screening using generalized estimating equations with a logit link function to account for site clustering, rurality, and country income. Of the 220 sites in the 2023 survey, 61% (134/220) reported cervical cancer screening by cytology or human papillomavirus (HPV) testing on‐site, and 88% (194/220) reported cervical cancer screening by any method, including visual inspection. At sites serving predominantly rural populations, 62% (29/47) exclusively performed screening by visual inspection. Overall, 23% (50/220) of sites performed cytology‐based anal cancer screening on‐site, and 16% (35/220) had availability of high‐resolution anoscopy, either on‐site or by referral. Screening for cancer of the liver, colon, lung, prostate, or breast (by imaging) were each available at less than 43% of sites. The odds of cervical cancer screening availability increased by 16% annually from 2017 through 2023 (aOR = 1.16, 95% CI: 1.07–1.27, p = 0.001), while the relative odds of anal cancer screening availability decreased by 9% annually (aOR = 0.91, 95% CI: 0.84–0.99, p = 0.023). Lack of trained staff was the most frequently reported barrier, followed by lack of equipment. Understanding current practices and capacity is essential for the continued integration of cancer prevention in HIV care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Institute of Infectious Diseases, Pune, India.
- Research Department, Fundacion Huesped, Buenos Aires, Argentina.
- Goodlife Access, Kigali, Rwanda.
- University of Rwanda, Kigali, Rwanda.
ORCID-Profile: Rachael A Pellegrino, Miriam Nakalembe, Eliane Rohner, Antoine Jaquet, Aggrey Semeere, Simon Boni
Förderung
- NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Pellegrino, R. A., Shepherd, B. E., Pujari, S., Fink, V., Murenzi, G., Nakalembe, M., Coburn, S. B., Rohner, E., Jaquet, A., Lade, C., Crabtree Ramirez, B., Anastos, K., Semeere, A., Park, L. S., Mokone, L., Boni, S., Somia, I. K. A., Jalil, E. M., Adedimeji, A., …, & International epidemiology Databases to Evaluate AIDS (IeDEA) (2026). Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium. International Journal of Cancer. https://doi.org/10.1002/ijc.70503
Vancouver
Pellegrino RA, Shepherd BE, Pujari S, Fink V, Murenzi G, Nakalembe M, et al. Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium. International Journal of Cancer. 2026. doi:10.1002/ijc.70503
BibTeX
@article{Pellegrino2026,
author = {Pellegrino, Rachael A and Shepherd, Bryan E and Pujari, Sanjay and Fink, Valeria and Murenzi, Gad and Nakalembe, Miriam and Coburn, Sally B and Rohner, Eliane and Jaquet, Antoine and Lade, Caroline and Crabtree Ramirez, Brenda and Anastos, Kathryn and Semeere, Aggrey and Park, Lesley S and Mokone, Limpho and Boni, Simon and Somia, I Ketut Agus and Jalil, Emilia M and Adedimeji, Adebola and Orang'o, Omenge and Silverberg, Michael J and Quarter, Kumbirai Pise and Messou, Eugène and Ross, Jeremy and Gotuzzo, Eduardo and Lelo, Patricia and Byakwaga, Helen and Ezechi, Oliver and Euvrard, Jonathan and Maruri, Fernanda and Achenbach, Chad J and Castilho, Jessica L and International epidemiology Databases to Evaluate AIDS (IeDEA), International epidemiology Databases to Evaluate AIDS (IeDEA)},
title = {Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70503}
}
EUVIMED